ホーム>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>NiCur

NiCur

カタログ番号GC62248

NiCur は、IC50 値が 0.35 μM の強力かつ選択的な CBP ヒストン アセチルトランスフェラーゼ (HAT) 阻害剤です。 CBP HAT 活性をブロックし、遺伝毒性ストレス時の p53 活性化をダウンレギュレートする NiCur。 NiCur は、標的タンパク質の発現に影響を与えることなく機構研究を行うために使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

NiCur 化学構造

サイズ 価格 在庫数 個数
5 mg
$180.00
在庫あり
10 mg
$315.00
在庫あり
25 mg
$585.00
在庫あり
50 mg
$855.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

NiCur is a potent and selective CBP histone acetyltransferase (HAT) inhibitor with an IC50 value of 0.35 μμ. NiCur, which blocks CBP HAT activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins[1].

NiCur (0.5~1 μM; U2OS cells) reduces the Dox-induced p53K382ac, p53S15p, and p53 levels in a dose-dependent manner[1].NiCur (1.5 μM) reduces the level of H3K27ac. NiCur (1.5 μM; U2OS cells) restores cellular proliferation. NiCur (Intestinal epithelial cells) down-regulates Dox-mediated p53 activation without affecting the levels of H2A.X S139p. NiCur can modulate the gene regulatory switch for reprogramming chromatin landscape. NiCur blocks CBP HAT activity[1].

[1]. Vincek AS, et al. Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3. Molecules. 2018;23(8):1930. Published 2018 Aug 2.

レビュー

Review for NiCur

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NiCur

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.